2017
Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC
Nathavitharana RR, Shi CX, Chindelevitch L, Calderon R, Zhang Z, Galea JT, Contreras C, Yataco R, Lecca L, Becerra MC, Murray MB, Cohen T. Polyclonal Pulmonary Tuberculosis Infections and Risk for Multidrug Resistance, Lima, Peru - Volume 23, Number 11—November 2017 - Emerging Infectious Diseases journal - CDC. Emerging Infectious Diseases 2017, 23: 1887-1890. PMID: 29048297, PMCID: PMC5652442, DOI: 10.3201/eid2311.170077.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisHost Mycobacterium tuberculosis diversityMultidrug-resistant TBInfectious Diseases journal - CDCPulmonary TB patientsPulmonary tuberculosis infectionTB patientsTuberculosis infectionPolyclonal infectionsSimple infectionMultidrug resistanceInfectionPatientsTuberculosisPrevalenceDiagnosis
2016
Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis
Kunkel A, Cobelens FG, Cohen T. Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis. PLOS Medicine 2016, 13: e1002142. PMID: 27727274, PMCID: PMC5058480, DOI: 10.1371/journal.pmed.1002142.Peer-Reviewed Original ResearchConceptsTreatment of tuberculosisMDR-TB treatmentTB treatmentSecondary casesDrug-resistant (XDR) TBResistance patternsLife expectancyMultidrug-resistant TB patientsDrug bedaquilineMDR-TB drugsAnti-tuberculosis drug bedaquilineCulture conversionMDR patientsTB patientsMortality benefitBedaquiline resistanceMedian timeRisk of resistanceTB drugsDecrease transmissionHypothetical cohortSources of heterogeneityDrug interactionsInitial cohortTime of initiation
2014
Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis
Shrestha S, Knight GM, Fofana M, Cohen T, White RG, Cobelens F, Dowdy DW. Drivers and Trajectories of Resistance to New First-Line Drug Regimens for Tuberculosis. Open Forum Infectious Diseases 2014, 1: ofu073. PMID: 25734143, PMCID: PMC4281792, DOI: 10.1093/ofid/ofu073.Peer-Reviewed Original ResearchDrug-resistant TBTreatment of tuberculosisNew drug regimenTransmission fitnessDrug regimensDrug regimenTreatment successDrug-susceptible TBAppropriate second-line therapyDR-TB prevalenceSecond-line therapyDrug resistance trendsTreatment success rateHigher treatment successNovel drug regimensEmergence of resistancePopulation-level dataTB regimensShort-term surveillanceDS-TBNew regimenClinical trialsEarly diagnosisRegimensDrug resistance